Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Agency Actions topic
No spam. Unsubscribe anytime.
CPRIT oversight committee approves FY25 awards, product development supplements, prevention grants and $300 million bond authorization
Summary
The Cancer Prevention and Research Institute of Texas oversight committee voted to approve multiple grant award slates across academic research, prevention and product development, authorized staff to negotiate and sign contracts, and approved a $300 million bond resolution to support grants and agency operations.
The Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee voted on a package of awards, contract delegations and financing on May 21 during its regular meeting in Austin.
Members approved the academic research program's slate of 47 awards requesting $69.7 million, approved six prevention awards, and approved a product-development supplemental slate funded from unused FY25 product-development dollars. The committee also delegated contract negotiation authority to the CEO and CPRIT staff for the approved awards and authorized the CEO to sign contracts on behalf of CPRIT. Members approved an agency request to authorize up to $300 million in bond financing for fiscal year 2026 through the Texas Public Finance Authority to fund prior-year awards and administrative expenses.
Why this matters: The votes move funding and contracting actions from recommendation to execution and free the agency to begin negotiating awards and contract terms for grantees and product-development companies. The bond authorization sets the finance capacity CPRIT intends to use next fiscal year to support previously approved grants and operations.
What the committee approved and related actions - Academic research: The committee approved the Program Integration Committee's recommendations for FY25 (47 awards, $69.7 million). Doctor Rosenfeld publicly reported a conflict of interest on RP250601 and did not vote on that recommendation; the remainder of the academic slates passed by the required two-thirds of members present. - Prevention: The committee approved six prevention grant recommendations from the Prevention Integration Committee and delegated contract negotiation and signature authority to the CEO and staff. - Product development: The committee approved eight supplemental product-development recommendations (using about $10 million of carryover funds) and delegated contract negotiation/signature authority; the chair also authorized advanced payments to the eight companies upon contract execution and tranche completion. - Contracts and operations: The committee approved renewal of the grant-management support services contract with General Dynamics Information Technology (GDIT) for FY26 and authorized staff to contract with a venue for the Innovation in X conference for up to $350,000. - Audit and finance: The committee approved internal audit reports (post-award grant monitoring; non-grant expenditures; purchase card advisory) and accepted the chief financial officer's revenues update. The oversight committee approved a bond issuance resolution authorizing TPFA financing of up to $300 million for FY26.
Quotes - “We will also have the university advisory committee presentation…including $93,000,000 in awards,” Chief Executive Officer’s report (CEO report). (excerpted from CEO report delivered by Ms. Doyle) - “I will note for the record that Doctor Rosenfeld did not vote on this recommendation,” Chair (recording Rosenfeld’s recusal on RP250601).
Next steps and implementation notes - Staff were authorized to negotiate contracts and sign on CPRIT’s behalf; execution and tranche milestones will govern disbursements. - The bond resolution will be transmitted to the Texas Public Finance Authority to support financing in FY26.
Votes at a glance (formal motions recorded in the transcript): - Approve minutes of Feb. 19 and March 21 oversight committee meetings — motion carried. - Approve PIC academic research recommendations for RP250601 (separate vote; Doctor Rosenfeld recused) — motion carried. - Approve PIC remaining academic research 46 recommendations — motion carried. - Delegate contract negotiation/signature authority to CEO and staff for academic awards — motion carried. - Approve FY26 academic research RFAs as presented — motion carried. - Approve PIC prevention recommendations (6 awards) and delegate negotiation/signature authority — motion carried. - Approve product development supplemental grants (DP250167 separately noted for conflict reporting) and remaining 7 supplemental awards — motions carried; delegated negotiation/signature authority for product-development awards — motion carried. - Authorize CPRIT to disperse advanced payments to the eight product development award recipients upon contract execution and tranche satisfaction — motion carried. - Approve internal audit reports (post-award grant monitoring, non-grant expenditures, purchase-card advisory) — motion carried. - Approve renewal of GDIT grant-management support services contract for FY26 — motion carried. - Authorize contracting for Innovation in X conference venue (not-to-exceed $350,000) — motion carried. - Approve fiscal year 2026 bond issuance resolution requesting up to $300 million from TPFA — motion carried.
Sources and provenance: See provenance entries linked to the transcript for the meeting’s CEO report, PIC presentations, prevention presentations, product development presentation, internal audit and CFO reports, and all recorded motions and votes.
